Kynomycin

Primary objective: To evaluate the safety and tolerability of single/multiple intravenous infusions of YB211 in healthy subjects. Secondary objectives: (1) To evaluate the pharmacokinetic (PK) characteristics of single/multiple intravenous infusions of YB211 in healthy subjects; (2) To evaluate the effect of blood concentration of YB211 on QT/QTc interval after single intravenous infusion in healthy subjects. Exploratory objectives: (1) To explore the changes of early renal injury indicators (kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), urinary β2-microglobulin (β2-MG)) compared with baseline after single/multiple intravenous infusions of YB211 in healthy subjects; (2) To explore the possible metabolites and metabolic pathways of YB211 after single intravenous infusion in healthy subjects.